Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299294 | 0.91 | L3MBTL3 (0.47) | MEN1KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL30299374 | 0.84 | SMN1; SMN2 (0.35) | MEN1KMT2AKDM4E | |
| SCHEMBL30299315 | 0.82 | LMNA (0.52) | ALDH1A1KDM4ETP53HRH3 | |
| SCHEMBL30299339 | 0.79 | HRH3 (0.39) | ALDH1A1KDM4EHRH3 | |
| SCHEMBL29928437 | 0.78 | L3MBTL3 (0.54) | ALDH1A1KDM4EL3MBTL3L3MBTL1HRH3 | |
| SCHEMBL30299283 | 0.75 | L3MBTL3 (0.54) | L3MBTL3L3MBTL1 | |
| SCHEMBL30299369 | 0.75 | AXL (0.37) | KMT2AALDH1A1KDM4EHRH3 | |
| SCHEMBL30299348 | 0.75 | GPR4 (0.42) | KMT2AALDH1A1KDM4ETSHRHRH3 | |
| SCHEMBL30090685 | 0.75 | SLC18A3 (0.39) | — | |
| SCHEMBL30090687 | 0.74 | AXL (0.38) | KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |